Inclusion Criteria

- Over 3 years of age with meningeal malignancies that are progressive or refractory to
conventional therapy. Patients with meningeal malignancies secondary to an
underlying solid tumor are eligible at initial diagnosis if there is no conventional
therapy.

- Patients with leukemia, lymphoma, or other solid tumor who also have overt meningeal
involvement by their tumor.

- Must have a life expectancy of at least 8 weeks and an ECOG performance status of 2
or better.

- Must sign an informed consent indicating that they are aware of the investigational
nature of this study.

- Patients must have recovered from the acute toxic effects of all prior intrathecal
chemotherapy, immunotherapy, or radiotherapy, prior to entering this study and must
be without significant systemic illness (e.g. infection). Patients must not have
received any CNS therapy within 1 week prior to starting treatment on this study or
craniospinal irradiation within 8 weeks prior to starting treatment on this study.
Patients must not have received intrathecal chemotherapy within 1 week (2 weeks if
prior DTC101).

- Must not have clinically significant abnormalities with regard to liver function,
renal function or metabolic parameters (electrolytes, calcium and phosphorus).

- Durable Power of Attorney (DPA): A DPA must be offered to all patients ≥ 18 years of
age.

Exclusion Criteria:

- Receiving other therapy (either intrathecal or systemic) designed specifically to
treat their meningeal malignancy are not eligible for this study. However, patients
receiving concomitant chemotherapy to control systemic or bulk CNS disease will be
eligible, provided the systemic chemotherapy is not a phase I agent, an agent which
significantly penetrates the CNS (e.g., high dose methotrexate, (> 1 gm/m2),
thiotepa, high dose cytarabine, (> 2 gm/m2 per day), 5-fluorouracil, intravenous
6-mercaptopurine or topotecan), or an agent known to have serious unpredictable CNS
side effects.

- Clinical evidence of obstructive hydrocephalus or compartmentalization of the CSF
flow as documented by a radioisotope Indium111 or Technitium99-DTPA flow study are
not eligible for this protocol. If a CSF flow block or compartmentalization is
demonstrated, focal radiotherapy to the site of block to restore flow and a repeat
CSF flow study showing clearing of the blockage is required for the patient to be
eligible for the study.

- Patients who have leukemia or lymphoma and a concomitant bone marrow relapse.

- Women of childbearing age must not be pregnant or lactating.

- Patients must not have received any other systemic investigational agent within 14
days prior to, or during, study treatment. The 14 day period should be extended if
the patient received any investigational agent which is known to have delayed
toxicities after 14 days. Patients must not have received any other intrathecal
investigational within 7 days prior to, or during, study treatment. The 7 day period
should be extended if the patient received any investigational agent which is known
to have delayed toxicities after 7 days or a prolonged half-life.